These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 27935553)

  • 1. Percutaneous irreversible electroporation (IRE) of prostate cancer: Contrast-enhanced ultrasound (CEUS) findings during follow up.
    Beyer LP; Pregler B; Nießen C; Michalik K; Haimerl M; Stroszczynski C; Jung EM; Wiggermann P
    Clin Hemorheol Microcirc; 2016; 64(3):501-506. PubMed ID: 27935553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Irreversible electroporation for the treatment of localized prostate cancer: a summary of imaging findings and treatment feedback.
    Scheltema MJ; Postema AW; de Bruin DM; Buijs M; Engelbrecht MR; Laguna MP; Wijkstra H; de Reijke TM; de la Rosette JJMCH
    Diagn Interv Radiol; 2017; 23(5):365-370. PubMed ID: 28830850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MRI and contrast-enhanced ultrasound imaging for evaluation of focal irreversible electroporation treatment: results from a phase I-II study in patients undergoing IRE followed by radical prostatectomy.
    van den Bos W; de Bruin DM; van Randen A; Engelbrecht MR; Postema AW; Muller BG; Varkarakis IM; Skolarikos A; Savci-Heijink CD; Jurhill RR; Zondervan PJ; Laguna Pes MP; Wijkstra H; de Reijke TM; de la Rosette JJ
    Eur Radiol; 2016 Jul; 26(7):2252-60. PubMed ID: 26449559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Percutaneous irreversible electroporation of hepatocellular carcinoma: Contrast-enhanced ultrasound-findings during 1-year follow-up.
    Niessen C; Beyer LP; Haimerl M; Schicho A; Stroszczynski C; Wiggermann P; Jung EM
    Clin Hemorheol Microcirc; 2019; 72(1):85-93. PubMed ID: 30584122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Percutaneous irreversible electroporation (IRE) of prostate cancer: Contrast-enhanced ultrasound (CEUS) findings.
    Niessen C; Jung EM; Beyer L; Pregler B; Dollinger M; Haimerl M; Scheer F; Stroszczynski C; Wiggermann P
    Clin Hemorheol Microcirc; 2015; 61(2):135-41. PubMed ID: 26410867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contrast enhanced ultrasound (CEUS) with parametric imaging after irreversible electroporation (IRE) of the prostate to assess the success of prostate cancer treatment.
    Jung EM; Engel M; Wiggermann P; Schicho A; Lerchbaumer M; Stroszczynski C; Fischer T; Wiesinger I
    Clin Hemorheol Microcirc; 2021; 77(3):303-310. PubMed ID: 33337354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety and efficacy of irreversible electroporation for the ablation of prostate cancer: a multicentre prospective human in vivo pilot study protocol.
    van den Bos W; de Bruin DM; Muller BG; Varkarakis IM; Karagiannis AA; Zondervan PJ; Laguna Pes MP; Veelo DP; Savci Heijink CD; Engelbrecht MRW; Wijkstra H; de Reijke TM; de la Rosette JJMCH
    BMJ Open; 2014 Oct; 4(10):e006382. PubMed ID: 25354827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Focal vs extended ablation in localized prostate cancer with irreversible electroporation; a multi-center randomized controlled trial.
    Scheltema MJ; van den Bos W; de Bruin DM; Wijkstra H; Laguna MP; de Reijke TM; de la Rosette JJ
    BMC Cancer; 2016 May; 16():299. PubMed ID: 27150293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ultrasound and Contrast-enhanced Ultrasound Findings after Percutaneous Irreversible Electroporation of Hepatic Malignant Tumors.
    Chai W; Xie L; Zhao Q; Cheng C; Tian G; Jiang T; Wu P
    Ultrasound Med Biol; 2020 Mar; 46(3):620-629. PubMed ID: 31924420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Irreversible Electroporation for the Ablation of Prostate Cancer.
    Karagiannis A; Varkarakis J
    Curr Urol Rep; 2019 Sep; 20(10):63. PubMed ID: 31478109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ultrasound and Contrast-Enhanced Ultrasound for Evaluation of Irreversible Electroporation Ablation: In Vivo Proof of Concept in Normal Porcine Liver.
    Lin MX; Kuang M; Xu M; Zhuang BW; Tian WS; Ye JY; Xie XH; Xie XY
    Ultrasound Med Biol; 2016 Nov; 42(11):2639-2649. PubMed ID: 27546157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Irreversible electroporation of hepatocellular carcinoma: preliminary report on the diagnostic accuracy of magnetic resonance, computer tomography, and contrast-enhanced ultrasound in evaluation of the ablated area.
    Granata V; de Lutio di Castelguidone E; Fusco R; Catalano O; Piccirillo M; Palaia R; Izzo F; Gallipoli AD; Petrillo A
    Radiol Med; 2016 Feb; 121(2):122-31. PubMed ID: 26345332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Image-guided Irreversible Electroporation of Localized Prostate Cancer: Functional and Oncologic Outcomes.
    Collettini F; Enders J; Stephan C; Fischer T; Baur ADJ; Penzkofer T; Busch J; Hamm B; Gebauer B
    Radiology; 2019 Jul; 292(1):250-257. PubMed ID: 31161973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of irreversible electroporation of prostate cancer on microcirculation: Imaging findings in contrast-enhanced T1-weighted 3D MRI.
    Beyer LP; Pregler B; Verloh N; Brünn K; Haimerl M; Stroszczynski C; Jung EM; Wiggermann P
    Clin Hemorheol Microcirc; 2017; 67(3-4):399-405. PubMed ID: 28885207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Chronologic Change in the Size and Contrast-Enhancement of Ablation Zones on CT Images after Irreversible Electroporation and Radiofrequency Ablation.
    Scheck J; Bruners P; Schindler D; Kuhl C; Isfort P
    Korean J Radiol; 2018; 19(4):560-567. PubMed ID: 29962862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Percutaneous irreversible electroporation (IRE) of hepatic malignant tumours: contrast-enhanced ultrasound (CEUS) findings.
    Wiggermann P; Zeman F; Niessen C; Agha A; Trabold B; Stroszczynski C; Jung EM
    Clin Hemorheol Microcirc; 2012; 52(2-4):417-27. PubMed ID: 22986756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Focal ablation of apical prostate cancer lesions with irreversible electroporation (IRE).
    Blazevski A; Amin A; Scheltema MJ; Balakrishnan A; Haynes AM; Barreto D; Cusick T; Thompson J; Stricker PD
    World J Urol; 2021 Apr; 39(4):1107-1114. PubMed ID: 32488359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Irreversible Electroporation of Malignant Hepatic Tumors--Alterations in Venous Structures at Subacute Follow-Up and Evolution at Mid-Term Follow-Up.
    Dollinger M; Müller-Wille R; Zeman F; Haimerl M; Niessen C; Beyer LP; Lang SA; Teufel A; Stroszczynski C; Wiggermann P
    PLoS One; 2015; 10(8):e0135773. PubMed ID: 26270651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Irreversible electroporation in patients with liver tumours: treated-area patterns with contrast-enhanced ultrasound.
    Zhou L; Yin S; Chai W; Zhao Q; Tian G; Xu D; Jiang T
    World J Surg Oncol; 2020 Nov; 18(1):305. PubMed ID: 33228665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncological and Quality-of-life Outcomes Following Focal Irreversible Electroporation as Primary Treatment for Localised Prostate Cancer: A Biopsy-monitored Prospective Cohort.
    Blazevski A; Scheltema MJ; Yuen B; Masand N; Nguyen TV; Delprado W; Shnier R; Haynes AM; Cusick T; Thompson J; Stricker P
    Eur Urol Oncol; 2020 Jun; 3(3):283-290. PubMed ID: 31103721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.